Actively Recruiting
Hepatic Venous Pressure Gradient Versus Endoscopic Ultrasound-Guided Portal Pressure Gradient - Comparative Analysis (HEPCA)
Led by Military University Hospital, Prague · Updated on 2026-02-20
40
Participants Needed
2
Research Sites
187 weeks
Total Duration
On this page
Sponsors
M
Military University Hospital, Prague
Lead Sponsor
U
University Hospital Prague (IKEM), Prague, Czech Republic
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this interventional trial is to compare in measuring of portal hypertension by HVPG and EUS-PPG in subject indicated to HVPG measurement. The primary question is whether EUS-PPG provides measurements really equivalent to HVPG in terms of gradient accuracy. Participants undergoing HVPG will first undergo the procedure while conscious, performed by the first operator. Immediately thereafter, HVPG will be repeated following the induction of anesthesia by a second operator blinded to the initial readings. Subsequently, EUS-PPG will be performed by an endoscopist, who will also be blinded to all previous pressure measurements.
CONDITIONS
Official Title
Hepatic Venous Pressure Gradient Versus Endoscopic Ultrasound-Guided Portal Pressure Gradient - Comparative Analysis (HEPCA)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-75 years at the time of enrollment with signed informed consent
- Clinical indication for HVPG measurement and/or transjugular liver biopsy for chronic advanced liver disease
You will not qualify if you...
- Severe co-morbidities such as advanced chronic heart failure, stage 4 or higher chronic renal insufficiency, or poorly compensated diabetes with severe complications
- Pregnancy
- Estimated patient non-compliance or refusal to sign informed consent
- Documented allergy to iodine contrast dye
- Presence of portal vein thrombosis, cavernomatous transformation of portal vein, or hepatic vein obstruction
- Grade 3 ascites
- Biliary obstruction
- Anticoagulation or antiplatelet therapy that cannot be stopped
- INR greater than 1.5 and/or platelet count less than 50,000/µl
- Hepatocellular carcinoma in the left lobe of the liver
- Surgically altered upper gastrointestinal tract anatomy
- Status after transjugular intrahepatic portosystemic shunt
- Status after liver transplantation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Military University Hospital Prague
Prague, Bohemia, Czechia, 16902
Actively Recruiting
2
IKEM
Prague, Czechia
Actively Recruiting
Research Team
P
Petr Hříbek, MD, PhD
CONTACT
P
Petr Urbánek, Prof.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here